As of June 2024, Forxiga (dapagliflozin) has expanded its approval for use in specific populations with Type 2 Diabetes (T2D).
While not a completely "new" medicine in 2024 as it has been previously approved, the important update is its expanded approval for younger patients. Forxiga is now approved in the EU and other countries for paediatric patients aged 10 years and above with T2D. This approval is based on the T2GO trial. For adults with T2D, Forxiga continues to be approved as an adjunct to diet and exercise to improve glycaemic control in 126 countries.
Key Takeaways Regarding Forxiga (Dapagliflozin):
- Approved for: Adults with T2D as an adjunct to diet and exercise to improve glycemic control.
- New in 2024: Approved for paediatric patients (10 years and older) with T2D in the EU and other countries.
- Mechanism: Works independently of insulin to help lower blood sugar levels.
- Status: Approved in 126 countries for adults with T2D; approval for paediatric use is more recent (EU and other countries).
- Approval Basis: T2GO trial for pediatric patients.
It's important to note that treatment options for diabetes are constantly evolving, and it is crucial to consult with a healthcare professional for personalized advice and treatment plans. They can provide the most up-to-date information on the latest medications and approaches for managing diabetes based on an individual's specific needs and medical history.
